Advertisement

Safety Profile of Ipatasertib Plus Abiraterone vs Placebo Plus Abiraterone in Metastatic Castration-resistant Prostate Cancer

Published:January 06, 2023DOI:https://doi.org/10.1016/j.clgc.2023.01.001

      Highlights

      • Adverse events (AEs) associated with ipatasertib plus abiraterone were manageable and reversible.
      • AEs appeared rapidly after the initiation of treatment and with limited recurrence.
      • Prophylactic measures can reduce the impact of AEs, as in other studies of ipatasertib.

      Abstract

      Purpose

      Adding ipatasertib to abiraterone and prednisone/prednisolone significantly improved radiographic progression-free survival for patients with metastatic castration-resistant prostate cancer (mCRPC) with PTEN-loss tumours by immunohistochemistry in the IPATential150 trial (NCT03072238). Here we characterise the safety of these agents in subpopulations and assess manageability of key adverse events (AEs).

      Materials and methods

      In this randomised, double-blind, phase 3 trial, patients with previously untreated asymptomatic or mildly symptomatic mCRPC were randomised 1:1 to receive ipatasertib-abiraterone or placebo-abiraterone (all with prednisone/prednisolone). AEs were analysed, focusing on key AEs of diarrhoea, hyperglycaemia, rash and transaminase increased.

      Results

      1097 patients received study medication and were assessed for safety (47% with PTEN-loss tumours by immunohistochemistry and 20% were Asian). Ipatasertib was associated with increased Grade 3/4 AEs and AEs leading to treatment discontinuation vs placebo. The rate of discontinuation of ipatasertib was 18% in patients with PTEN-loss and 21% overall. The frequencies of all-grade, Grade 3/4 and serious AEs were similar between the PTEN-loss and overall populations. Diarrhoea, hyperglycaemia, rash and transaminase elevation were more frequent in ipatasertib-treated patients, appearing rapidly after treatment initiation (median onset: 8-43 days for ipatasertib arm and 56-104 days for placebo). The ipatasertib discontinuation rate was 32% and 18% in Asian and non-Asian patients, respectively, despite similar baseline characteristics and Grade 3/4 AE frequencies between groups.

      Conclusions

      Ipatasertib plus abiraterone had an overall tolerable safety profile consistent with known toxicities. More AEs leading to drug discontinuation were observed with ipatasertib than placebo, but incidence would likely be lessened with prophylactic measures.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Clinical Genitourinary Cancer
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Song M
        • Bode AM
        • Dong Z
        • et al.
        AKT as a therapeutic target for cancer.
        Cancer Res. 2019; 79: 1019-1031
        • Afify SM
        • Oo AKK
        • Hassan G
        • et al.
        How can we turn the PI3K/AKT/mTOR pathway down? Insights into inhibition and treatment of cancer.
        Expert Rev Anticancer Ther. 2021; 21: 605-619
        • Shorning BY
        • Dass MS
        • Smalley MJ
        • et al.
        The PI3K-AKT-mTOR pathway and prostate cancer: at the crossroads of AR, MAPK, and WNT signaling.
        Int J Mol Sci. 2020; 21: 4507
        • Robinson D
        • Van Allen EM
        • Wu YM
        • et al.
        Integrative clinical genomics of advanced prostate cancer.
        Cell. 2015; 161: 1215-1228
        • Taylor BS
        • Schultz N
        • Hieronymus H
        • et al.
        Integrative genomic profiling of human prostate cancer.
        Cancer Cell. 2010; 18: 11-22
        • Ferraldeschi R
        • Nava Rodrigues D
        • Riisnaes R
        • et al.
        PTEN protein loss and clinical outcome from castration-resistant prostate cancer treated with abiraterone acetate.
        Eur Urol. 2015; 67: 795-802
        • Lazaro G
        • Kostaras E
        • Vivanco I.
        Inhibitors in AKTion: ATP-competitive vs allosteric.
        Biochem Soc Trans. 2020; 48: 933-943
        • de Bono JS
        • De Giorgi U
        • Rodrigues DN
        • et al.
        Randomized Phase II study evaluating Akt blockade with ipatasertib, in combination with abiraterone, in patients with metastatic prostate cancer with and without PTEN loss.
        Clin Cancer Res. 2019; 25: 928-936
        • Sweeney C
        • Bracarda S
        • Sternberg CN
        • et al.
        Ipatasertib plus abiraterone and prednisolone in metastatic castration-resistant prostate cancer (IPATential150): a multicentre, randomised, double-blind, phase 3 trial.
        Lancet. 2021; 398: 131-142
        • Oliveira M
        • Saura C
        • Nuciforo P
        • et al.
        FAIRLANE, a double-blind placebo-controlled randomized phase II trial of neoadjuvant ipatasertib plus paclitaxel for early triple-negative breast cancer.
        Ann Oncol. 2019; 30: 1289-1297
        • Kim SB
        • Dent R
        • Im SA
        • et al.
        Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.
        Lancet Oncol. 2017; 18: 1360-1372
      1. Schmid P, Loirat D, Savas P, et al. Phase 1b study evaluating a triplet combination of ipatasertib, atezolizumab, and paclitaxel or nab-paclitaxel as first-line therapy for locally advanced/metastatic triple-negative breast cancer. AACR 2019. Abstract CT 049.

      2. Schmid P, Savas P, Espinosa E, et al. Phase 1b study evaluating a triplet combination of ipatasertib (IPAT), atezolizumab, and taxanes (TAX) as first-line therapy for locally advanced/metastatic triple-negative breast cancer (TNBC). SABCS 2020. Poster PS12-28.

      3. Dent R, Kim S-B, Oliveira M, et al. Double-blind placebo-controlled randomized phase III trial evaluating first-line ipatasertib combined with paclitaxel for PIK3CA/AKT1/PTEN-altered locally advanced unresectable or metastatic triple-negative breast cancer: primary results from IPATunity130 Cohort A. SABCS 2020. Abstract GS3-04.

        • Zhu Y
        • Mo M
        • Wei Y
        • et al.
        Epidemiology and genomics of prostate cancer in Asian men.
        Nat Rev Urol. 2021; 18: 282-301
        • Shi Z
        • Sweeney C
        • Bracarda S
        • et al.
        Biomarker analysis of the Phase III IPATential150 trial of first-line ipatasertib (Ipat) plus abiraterone (Abi) in metastatic castration-resistant prostate cancer (mCRPC).
        J Clin Oncol. 2020; 38: 182
        • Bernard B
        • Muralidhar V
        • Chen YH
        • et al.
        Impact of ethnicity on the outcome of men with metastatic, hormone-sensitive prostate cancer.
        Cancer. 2017; 123: 1536-1544
        • Poon DMC
        • Chan T
        • Chan K
        • et al.
        Preliminary efficacy and tolerability of chemohormonal therapy in metastatic hormone-naive prostate cancer: the first real-life experience in Asia.
        Asia Pac J Clin Oncol. 2018; 14: 347-352
        • Aggarwal R
        • Grabowsky J
        • Strait N
        • et al.
        Impact of patient ethnicity on the metabolic and immunologic effects of PI3K-mTOR pathway inhibition in patients with solid tumor malignancies.
        Cancer Chemother Pharmacol. 2014; 74: 359-365
        • Nunnery SE
        • Mayer IA.
        Management of toxicity to isoform alpha-specific PI3K inhibitors.
        Ann Oncol. 2019; 30: x21-x26
        • Crabb SJ
        • Griffiths G
        • Marwood E
        • et al.
        Pan-AKT inhibitor capivasertib with docetaxel and prednisolone in metastatic castration-resistant prostate cancer: a randomized, placebo-controlled phase ii trial (ProCAID).
        J Clin Oncol. 2021; 39: 190-201
      4. Turner N, Dent R, O'Shaughnessy J, et al. Ipatasertib + paclitaxel for PIK3CA/AKT1/PTEN altered hormone receptor-positive HER2-negative advanced breast cancer: primary results from Cohort B of the IPATunity130 randomised trial. Oral presentation at: ESMO 2020. Abstract 283MO.

        • Andre F
        • Ciruelos E
        • Rubovszky G
        • et al.
        Alpelisib for PIK3CA-mutated, hormone receptor-positive advanced breast cancer.
        N Engl J Med. 2019; 380: 1929-1940
        • Rugo HS
        • Andre F
        • Yamashita T
        • et al.
        Time course and management of key adverse events during the randomized phase III SOLAR-1 study of PI3K inhibitor alpelisib plus fulvestrant in patients with HR-positive advanced breast cancer.
        Ann Oncol. 2020; 31: 1001-1010
        • Doi T
        • Fujiwara Y
        • Matsubara N
        • et al.
        Phase I study of ipatasertib as a single agent and in combination with abiraterone plus prednisolone in Japanese patients with advanced solid tumors.
        Cancer Chemother Pharmacol. 2019; 84: 393-404
        • Yoshida K
        • Wilkins J
        • Winkler J
        • et al.
        Population pharmacokinetics of ipatasertib and its metabolite in cancer patients.
        J Clin Pharmacol. 2021; 61: 1579-1591
        • Fan WL
        • Shiao MS
        • Hui RC
        • et al.
        HLA association with drug-induced adverse reactions.
        J Immunol Res. 2017; 20173186328
        • Yan S
        • Chen SA
        • Zhang W
        • et al.
        HLA-A*02 alleles are associated with tetanus antitoxin-induced exanthematous drug eruptions in Chinese patients.
        Pharmacogenet Genom. 2016; 26: 538-546